Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Other Non-Current Assets (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Other Non-Current Assets for 14 consecutive years, with $5.2 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets fell 22.04% to $5.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.2 million through Dec 2025, down 22.04% year-over-year, with the annual reading at $5.2 million for FY2025, 22.04% down from the prior year.
  • Other Non-Current Assets hit $5.2 million in Q4 2025 for Corcept Therapeutics, down from $8.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $8.3 million in Q2 2025 to a low of $1.8 million in Q2 2022.
  • Historically, Other Non-Current Assets has averaged $5.4 million across 5 years, with a median of $5.1 million in 2022.
  • Biggest five-year swings in Other Non-Current Assets: plummeted 55.7% in 2022 and later skyrocketed 140.62% in 2023.
  • Year by year, Other Non-Current Assets stood at $3.1 million in 2021, then surged by 64.06% to $5.1 million in 2022, then grew by 29.32% to $6.5 million in 2023, then increased by 1.05% to $6.6 million in 2024, then dropped by 22.04% to $5.2 million in 2025.
  • Business Quant data shows Other Non-Current Assets for CORT at $5.2 million in Q4 2025, $8.0 million in Q3 2025, and $8.3 million in Q2 2025.